Revolution Medicines, Inc. (RVMD) Stock

Revolution Medicines, Inc. (RVMD) is a Healthcare stock trading at $162.89 (as of 2026-06-18), with a market capitalization of $33.48B and a trailing P/E of -22.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies aimed at RAS-addicted cancers. Its pipeline includes inhibitors such as SHP2, SOS1, and mTORC1 signaling, along with mutant- and RAS-variant specific KRAS and NRAS inhibitors, for solid tumor patients.

Valuation — source: SEC EDGAR (first-party)
Price	$162.89
Market Cap	$33.48B
P/E Ratio	-22.1
EV / EBITDA	-24.0
Price / Book	22.32
DCF Value (model)	$-76.53
DCF Upside vs Price	-147.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-91.5%
Current Ratio	6.80
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-7.3%
FCF Growth (YoY)	58.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	24.31 (safe)

Valuation vs Sector & Industry
Stock P/E	-22.1
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-205.7%
vs Industry	-228.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($1.33B)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Mark A. Goldsmith
Employees	616
Country	US
IPO Date	2020-02-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.